Vasoactive intestinal peptide receptors: A molecular target in breast and lung cancer

Current Pharmaceutical Design

Volumn 13, Issue 11, 2007, Pages 1099-1104

  Moody, Terry W ^a   Gozes, Illana ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Breast cancer; Lung cancer; PACAP; Receptors; VIP

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ELLIPTICINE DERIVATIVE; GEMCITABINE; GROWTH HORMONE RELEASING FACTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; IRINOTECAN; MESSENGER RNA; NAVELBINE; NEUROTENSIN[6-11] VASOACTIVE INTESTINAL POLYPEPTIDE[7-28]; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; RETINOIC ACID; RO 25 1553; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE LEUCYLALANYLLEUCYLALANINE ELLIPTICINE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; DRUG POTENTIATION; HUMAN; ISOTOPE LABELING; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SECOND MESSENGER; TUMOR BIOPSY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE;

EID: 34248340573     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780619000     Document Type: Review

References (69)

1. Dickson RB, Lippman ME. Molecular biology of breast cancer. In: DeVita Jr VT, Hellman S, Rosenberg SA Eds, Cancer: Principles & practice of oncology. Philadelphia, Lippincott-Raven Press 2001; 1633-51.
2. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-70.
3. Wolff AC, Abeloff MD. Adjuvant therapy for postmenopausal lymph node-negative breast cancer: It ain't necessarily so. J Natl Cancer Inst 2002; 94: 1041-3.
4. Landis S, Murray T, Bolden S, Wingo PCA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
5. Winer EP, Morrow M, Osborne CK, Harris JR. Malignant tumors of the breast. In: DeVita Jr VT, Hellman S, Rosenberg SA Eds, Cancer: Principles & practice of oncology. Philadelphia, Lippincott-Raven Press 2001; 1651-717.
6. Fisher B, Costantino JP, Wickerham DL, Cecchini WM, Cronin WM, Robidoux, A et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst 2005; 97: 1652-62.
7. Gespach C, Bawab W, Decremoux P, Calvo F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res 1998; 48: 5079-83.
8. Waschek JL, Richards ML, Bravo DT. Differential expression of VIP/PACAP receptor genes in breast, intestinal and pancreatic cancer cell lines. Cancer Lett 1995; 92:143-9.
9. Zia H, Hida T, Jakowlew S, Birrer M, Gozes Y, Reubi JC, et al. Breast cancer growth is inhibited by VIPhybrid, a synthetic VIP receptor antagonist. Cancer Res 1996; 56: 3486-9.
10. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol Med 1996; 74: 589-607.
11. Casibang M, Purdom S, Zia F, Jakowlew S, Neckers L, Ben-Av P, et al. Prostaglandin E2 and VIP increases vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer 2001; 31:203-12.
12. Moody TW, Walters J, Casibang M, Zia F, Gozes Y. VPAC1 receptors and lung cancer. Ann N.Y. Acad Sci USA 2000; 921: 26-32.
13. Moody TW, Leyton J, Chan D, Brenneman DC, Fridkin M, Gelber E, et al. VIP receptor antagonists potentiate the action of chemotherapeutic drugs on breast cancer cells. Breast Cancer Res and Treatment 2001; 68: 55-64.
14. Gelber E, Granoth R, Fridkin M, Dreznik Z, Brenneman DE, Moody TW, et al. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer 2001; 92: 2172-80.
15. Moody TW, Czerwinski G, Tarasova NI, Michejda CJ. VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life Sci 2002; 19: 1005-14.
16. Gozes I, Bodner M, Shwratz H, Shani T, Fridkin M. Studies toward the biosynthesis of vasoactive intestinal peptide. Peptides 1984; 5: 161-6.
17. Moody TW, Chan D, Fahrenkrug J, Jensen RT. Neuropeptides as autocrine growth factors in cancer cells. Current Pharm Design 2003; 9: 495-509.
18. Davidson A, Moody TW, Gozes I. Regulation of VIP gene expression. Molecular and Cellular Neurosci 1996; 7: 99-110.
19. Said SI, Mutt V. Polypeptide with broad biological activity: Isolation from small intestine. Science 1970; 69: 1217-8.
20. Miyata A, Jiang L, Dahl RD, Kitada, C, Kubo K, Fujino M, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 1990; 170: 643-8.
21. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-74.
22. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, et al. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 2000; 275: 24003-12.
23. Igarashi H, Ito T, Hou W, Mantey SA, Pradhan TK, Ulrich CD, et al. Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat and guinea pig. J Pharmacol Exp Ther 2002; 301: 37-50.
24. Gardner JD, Conlon TP, Fink ML, Bodanszky M. Interaction of peptides related to secretin with hormone receptors on pancreatic acinar cells. Gastroenterology 1976; 71: 965-70.
25. Christophe J, Svoboda M, Waelbroeck M, Win J, Robberecht P. Vasoactive intestinal peptide receptors in pancreas and liver. Ann NY Acad Sci 1988; 527: 238-56.
26. Fishbein VA, Coy DH, Hocart SJ, Jiang NY, Mrozinski Jr JE, Mantey SA, et al. A chimeric VIP-PACAP analogue but not VIP pseudopeptides. function as VIP receptor antagonists. Peptides 1994; 15: 95-100.
27. Leyton J, Gozes Y, Pisegna J, Coy D, Purdom S, Casibang M, et al. PACAP receptors are present in breast cancer cells. Breast Cancer Res Treat 1999; 56: 177-86.
28. Pandol SJ, Dharmsathaphorn K, Schoeffield MS, Vale W, Rivier J. Vasoactive intestinal peptide receptor antagonists [4Cl-D-Phe6,Leu17]VIP. Am J Physiol 1986; 250: G553-7.
29. Waelbroeck M, Robberecht P, Coy DH, Camus JC, DeNeef P, Christophe J. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyrl, D-Phe2)-GRP(1-29)NH2 as a VIP antagonist. Endocrinology 1985; 116: 2643-9.
30. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, et al. A hybrid antagonist to vasoactive intestinal peptide: Effects on cellular function in the central nervous system. J Pharm Exp Ther 1991; 257: 959-66.
31. Moody TW, Leyton J, Coelho T, Knight M, Takahashi K, Koh M, et al. (Stearyl, Norleucine17)VIPhyb is a potent non-small lung cancer VIP receptor antagonist. Life Sci 1997; 17: 1657-66.
32. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992; 8: 811-9.
33. Lutz EM, Sheward WJ, West KM, Morrow JA, Harmar AJ. The VIP2 receptor: Molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1993; 334: 3-8.
34. Pisegna J, Wank SA Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci USA 1993; 90: 6345-9.
35. Spengler D, Waeber C, Pantaloni C, Holsboe F, Bockaert J, Seeberg P, et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993; 365: 170-5.
36. Gourlet P, Vandermeers A, Vertongen P, Rathe J, DeNeef P, Cnuddle J, et al. Development of high affinity selective VIP1 receptor agonists. Peptides 1997; 18: 1539-45.
37. Bolin DR, Michelewsky J, Wasserman MA, O'Donnell M. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 1995; 37: 57-66.
38. Reubi JC. Neuropeptide reccceptors in health and disease: The molecular basis for in vivo imaging. J Nucl Med 1995; 36: 25-35.
39. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000; 60: 3105-12.
40. Busto R, Prieto JC, Bodega G, Zapatero J, Fogue L, Carrero O. VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: A study in biopsy specimens. Peptides 2003; 24: 429-36.
41. Moody TW, Zia F, Bitar K, Coy DH. In: Rosselin G Ed, PACAP(6-38) is a PACAP type 1 receptor antagonist on small cell lung cancer cells. VIP, PACAP and related regulatory peptides: From molecular biology to clinical applications. Singapore, World Scientific Publishing Co. 1994; 527-34.
42. Lee M, Jensen RT, Huang SC, Bepler G, Korman L, Moody TW. Vasoactive intestinal peptide binds with high affinity to non-small cell lung cancer cells and elevates cAMP levels. Peptides 1990; 11: 1205-10.
43. Shaffer MM, Carney DN, Korman LY, Lebovic GS, Moody TW. High affinity binding of VIP to lung cancer cell lines. Peptides 1987; 8: 1101-6.
44. Luis J, Said SI. Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines. Peptides 1990; 11: 1239-44.
45. Moody TW, Lee M, Kris RM, Bellot F, Bepler G, Oie H, et al. Lung carcinoid cell lines have bombesin-like peptides and EGF receptors. J Cellular Biochem 1990; 11: 139-47.
46. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. New Eng J Med 1994; 331: 1116-21.
47. Raderer M, Kurtaran A, Leimer M, Angelberger P, Niederle B, Vierhapper H, et al. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Pheloctreotide in 194 carcionoid patients: Vienna University Experience, 1993-1998. J Clin Oncol 2000; 18: 1331-6.
48. Pallela VR, Thakur ML, Chakder S, Rattan S. 99mTc-labeled vasoactive intestinal peptide receptor agonist: Functional studies. J Nucl Med 1999; 93: 352-60.
49. Weiner R, Thakur M. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 2003; 51: 749-63.
50. Moody TW, Leyton J, Unsworth E, John C, Lang L, Eckelman W. (Arg15, Arg21)VIP: A VIP agonist for localizing breast cancer tumors. Peptides 1998; 19: 585-92.
51. Korman LY, Carney DN, Citron ML, Moody TW. Secretin/VIP stimulated secretion of bombesin-like peptides from human small cell lung cancer. Cancer Res. 1986; 46: 1214-8.
52. Pisegna JR, Wank SA. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclasae and phospholipase C. J Biol Chem 1996; 271: 17267-74.
53. Moody TW, Leyton J, Casibang M, Pisegna J, Jensen RT. PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Reg Peptides 2002; 109: 135-40.
54. Leyton J, Coelho T, Hida T, Jakowlew S, Birrer M, Fridkin M, et al. PACAPhybrid antagonizes PACAP receptor splice variants. Life Sci 1997; 61: 631-9.
55. O'Dorisio MS, Fleshman DJ, Qualman SJ, O'Dorisio TM. Vasoactive intestinal peptide as an autocrine growth factor in neuroblastoma. Reg Peptides 1992; 37: 213-26.
56. Fruhwald MC, O'Dorisio MS, Fleitz J, Pietsch T, Reubi, JC. Vasoactive intestinal peptide (VIP) and VIP receptors: Gene expression and growth modulation in medulloblastoma, and other central primitive neuroectodermal tumors of childhood. Int J Cancer 1999, 81: 165-73.
57. Maruno K, Said SI. Small-cell lung carcinoma: Inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody. Life Sci 1993; 52: 267-71.
58. Gressons P, Paindaveine B, Hill JM, Evrard P, Brenneman DE. Vasoactive intestinal peptide shortens both G1 and S phases of neural cell cycle in whole postimplantation cultured mouse embryos. Eur J Neurosci 1998; 10: 1734-42.
59. Wu K, Kim HT, Rodriguez, JL, Munoz-Medellin D, Moshsin SK, Hilsenbeck SG, et al. 9-Cis retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen transgenic mice. Clin Cancer Res 2000; 6: 3696-704.
60. Moody TW, Dudek J, Zakowicz H, Walters J, Jensen RT, Petricoin EM, et al. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40 transgenic mice. Life Sci 2004; 74: 1345-57.
61. Madsen B, Georg B, Vissing H, Fahrenkrug J. Retinoic acid down regulates the expression of the vasoactive intestinal receptor. Cancer Res 1998; 58: 4845-50.
62. Jakowlew S, Zakowicz,H, Moody TW. Retinoic acid increased VPAC1 receptors and transforming growth factor β2 in non-small cell lung cancer cells. Peptides 1999; 21: 1831-7.
63. Steingart RA, Heldenberg E, Pinhasov A, Brenneman DE, Fridkin M, Gozes, A vasoactive intestinal peptide receptor analog alters the expression of homeobox. genes. Life Sci 2002; 71: 2543-52.
64. Moody TW, Zia F, Draoui M, Brenneman DE, Fridkin M, Davidson A, et al. A novel VIP antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci USA 1993; 90: 4345-9.
65. Sekido Y, Fong WM, Minna JD. In: DeVita VT, Hellman S, Rosenberg SA Eds, Molecular biology of lung cancer. Cancer: Principles and practice of oncology, Philadelphia, Lippincott-Raven Press 2001; 917-25.
66. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
67. Chen E. X, Siu L. L. Development of molecular targeted anticancer agents: Successes, failures and future directions. Curr Pharm Des 2005; 11(2): 265-72.
68. Ruano-Ravina A, Figueiras A, Freire-Garabal M, Barros-Dios J. M. Antioxidant vitamins and risk of lung cancer. Curr Pharm Des 2006; 12(5): 599-613.
69. Sauer G, Kurzeder C, Heilmann V, Kreienberg R, Deissler H. Immunotherapy and cancer vaccines in the management of breast cancer. Curr Pharm Des 2005; 11(27): 3475-83.